A Phase 2 interventional study of Cebranopadol 100 µg and Cebranopadol 300 µg in Chronic Pain, Diabetic Neuropathies and Diabetes Mellitus, sponsored by Tris Pharma, Inc.. Completed at 82 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Tris Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Chronic Pain with a site in Germany — 11 open to participants now, 14 under way, 8 of them phase 3. Chronic Pain · Germany.
Among the 70 studies in Chronic Pain with a site in Germany, this one has the largest enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2013, is one of 5 in phase 2, and was the 22nd registered.
3,227 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →11 of the 70 studies in Chronic Pain with a site in Germany are open now. Recruiting first, the newest first:
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 17 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 699 is above the median of 60 across 2,387 interventional studies indexed under Chronic Pain.
Median enrollment 91 across the 50 interventional studies, 167 across the 20 observational. Of the 54 that completed or were terminated, 21 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 70 have an industry lead sponsor. The 10 most frequent:
Tris Pharma, Inc. is the lead sponsor of 22 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 4 (31%) have results posted.
Tris Pharma, Inc. has 4 studies filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Pain with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06784141Prof. Dr. Julia GlombiewskiNetwork-Based vs. Standardized Cognitive Behavioral Therapy in Chronic Primary Pain | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies in Chronic Pain with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to evaluate if cebranopadol is safe and can decrease pain in patients when compared to placebo (a tablet that does not contain active product) and when compared to a marketed product containing pregabalin (Lyrica®). Furthermore, this trial will be undertaken to find out if the patient's general health and well-being improves under trial treatment.
The concentrations of cebranopadol in the blood will be investigated to get a better understanding of how it is absorbed from the gut, distributed and broken down in the body, and eliminated from the body.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cebranopadol 300 µg
Drug: Cebranopadol 600 µg
Drug: Pregabalin
Drug: Matching Placebo
Drug: Cebranopadol 100 µg
Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
Also known as: Lyrica®
Placebo will be matched to pregabalin and cebranopadol.
Change in Average Pain Intensity.
Participants will be asked to record their pain intensity in the evening. Participants are asked to rate how much pain they had on average in the past 24 hours. The participant scores their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". Baseline average pain scores are calculated from the averages of all scores recorded during the 3 days prior to randomization. The average pain at week 6 will be the average pain scores calculated from all pain scores measured during week 6.
Time frame: Baseline; to End of Week 6 of the Maintenance Phase
The trial started on 27 Sep 2013 with the enrollment of the first participants and was completed on 28 Jan 2015 when the last participant completed the last follow-up examination according to the protocol.
| Milestone | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo |
|---|---|---|---|---|---|
| Started | 66 | 64 | 65 | 68 | 66 |
| Allocated set excl. non-compliant sites | 64 | 61 | 63 | 65 | 63 |
| Safety set | 64 | 61 | 62 | 65 | 62 |
| Full analysis set | 64 | 60 | 61 | 65 | 62 |
| Per protocol set | 58 | 55 | 50 | 51 | 49 |
| Completed | 52 | 41 | 27 | 51 | 48 |
| Not completed | 14 | 23 | 38 | 17 | 18 |
| Withdrew: Adverse event | 8 | 17 | 30 | 8 | 5 |
| Withdrew: Lack of efficacy | 2 | 1 | 1 | 1 | 3 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 2 | 2 | 3 |
| Withdrew: Inclusion criteria not met | 0 | 1 | 1 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 2 | 2 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Gcp non-compliance at site | 2 | 3 | 2 | 3 | 3 |
Participants will be asked to record their pain intensity in the evening. Participants are asked to rate how much pain they had on average in the past 24 hours. The participant scores their pain intensity on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine". Baseline average pain scores are calculated from the averages of all scores recorded during the 3 days prior to randomization. The average pain at week 6 will be the average pain scores calculated from all pain scores measured during week 6.
| units on a scale | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo |
|---|---|---|---|---|---|
| Change in Average Pain Intensity. | -2.24 (-2.78 to -1.70) | -2.28 (-2.86 to -1.71) | -2.56 (-3.20 to -1.91) | -2.79 (-3.33 to -2.26) | -1.55 (-2.10 to -1.00) |
Collected over Safety Analysis Set Baseline Visit (Day 1) to End of Maintenance Phase (Day 57).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cebranopadol 100 µg | 0/64 (0%) | 1/64 (1.6%) | 47/64 (73.4%) |
| Cebranopadol 300 µg | 0/61 (0%) | 2/61 (3.3%) | 50/61 (82%) |
| Cebranopadol 600 µg | 0/62 (0%) | 4/62 (6.5%) | 53/62 (85.5%) |
| Pregabalin | 0/65 (0%) | 1/65 (1.5%) | 49/65 (75.4%) |
| Matching Placebo | 0/62 (0%) | 2/62 (3.2%) | 43/62 (69.4%) |
| Event | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo |
|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 0/64 | 0/61 | 2/62 | 0/65 | 0/62 |
| Diabetes MellitusMetabolism and nutrition disorders | 0/64 | 1/61 | 0/62 | 0/65 | 0/62 |
| Renal Failure AcuteRenal and urinary disorders | 0/64 | 1/61 | 0/62 | 0/65 | 0/62 |
| Abdominal PainGastrointestinal disorders | 0/64 | 0/61 | 1/62 | 0/65 | 1/62 |
| Gastrooesophageal Reflux DiseaseGastrointestinal disorders | 0/64 | 0/61 | 1/62 | 0/65 | 0/62 |
| Peripheral SwellingGeneral disorders | 0/64 | 0/61 | 0/62 | 0/65 | 1/62 |
| DehydrationMetabolism and nutrition disorders | 0/64 | 0/61 | 1/62 | 0/65 | 0/62 |
| Hypoglycaemic ComaNervous system disorders | 0/64 | 0/61 | 1/62 | 0/65 | 0/62 |
| HaematomaVascular disorders | 1/64 | 0/61 | 0/62 | 0/65 | 0/62 |
| Diverticulum Intestinal HaemorrhagicGastrointestinal disorders | 0/64 | 0/61 | 0/62 | 1/65 | 0/62 |
| Event | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/64 | 22/61 | 16/62 | 6/65 | 6/62 |
| DizzinessNervous system disorders | 8/64 | 10/61 | 21/62 | 12/65 | 6/62 |
| VomitingGastrointestinal disorders | 2/64 | 10/61 | 17/62 | 1/65 | 2/62 |
| FatigueGeneral disorders | 8/64 | 11/61 | 10/62 | 5/65 | 2/62 |
| SomnolenceNervous system disorders | 3/64 | 8/61 | 8/62 | 3/65 | 1/62 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 3/64 | 8/61 | 6/62 | 1/65 | 2/62 |
| Dry mouthGastrointestinal disorders | 1/64 | 1/61 | 8/62 | 1/65 | 1/62 |
| ConstipationGastrointestinal disorders | 3/64 | 6/61 | 7/62 | 6/65 | 2/62 |
| Abdominal pain upperGastrointestinal disorders | 0/64 | 6/61 | 0/62 | 0/65 | 2/62 |
| HeadacheNervous system disorders | 3/64 | 6/61 | 3/62 | 4/65 | 2/62 |
Full Analysis Set
| Age, Continuous(years) | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 62.2 ± 8.6 | 61.6 ± 8.7 | 62.2 ± 8.1 | 61.7 ± 9.9 | 63.3 ± 10.3 | 62.2 ± 9.1 |
| Sex: Female, Male(Participants) | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 20 | 23 | 22 | 16 | 13 | 94 |
| Male | 44 | 38 | 40 | 49 | 49 | 220 |
| Ethnicity (NIH/OMB)(Participants) | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 6 | 10 | 5 | 34 |
| Not Hispanic or Latino | 57 | 55 | 56 | 55 | 57 | 280 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 1 | 0 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 | 4 | 1 | 9 |
| White | 61 | 58 | 57 | 58 | 61 | 295 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 2 | 3 | 0 | 6 |
| Region of Enrollment(participants) | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Austria | 5 | 6 | 5 | 6 | 5 | 27 |
| Netherlands | 3 | 3 | 4 | 2 | 4 | 16 |
| United States | 13 | 10 | 9 | 13 | 10 | 55 |
| Denmark | 2 | 2 | 2 | 1 | 2 | 9 |
| Italy | 2 | 2 | 2 | 2 | 1 | 9 |
| France | 7 | 7 | 8 | 8 | 8 | 38 |
| Germany | 31 | 30 | 30 | 32 | 31 | 154 |
| Spain | 1 | 1 | 2 | 1 | 1 | 6 |
| Height(meter) | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 1.721 ± 0.098 | 1.736 ± 0.092 | 1.717 ± 0.104 | 1.736 ± 0.110 | 1.736 ± 0.076 | 1.729 ± 0.097 |
| Weight(kilogram) | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 95.77 ± 15.62 | 96.51 ± 18.12 | 93.72 ± 16.05 | 92.25 ± 17.28 | 99.00 ± 15.99 | 95.42 ± 16.69 |
| BMI(kilogram per square meter) | Cebranopadol 100 µg | Cebranopadol 300 µg | Cebranopadol 600 µg | Pregabalin | Matching Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 32.30 ± 4.41 | 31.87 ± 4.39 | 31.70 ± 4.29 | 30.66 ± 5.26 | 32.80 ± 4.53 | 31.86 ± 4.62 |
4 further baseline measures are reported on the registry.
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2013 to primary completion in Jan 2015, 16 months.
Results were first posted in Dec 2019, 4 years 11 months after primary completion.
Of 60 phase 2 interventional studies under Chronic Pain, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 52. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cebranopadol